3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
5
Recruiting
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma, Mantle-Cell
7
Lymphoma, Non-Hodgkin
5
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, B-Cell
3
Leukemia
3
Lymphoma, Follicular
2
Lymphoma
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Lymphoid
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Chromosome 17 deletion
1
Burkitt Lymphoma
1
Interventions
venetoclax
1
pirtobrutinib
1
nirogacestat
1
ibrutinib
1
fludarabine phosphate
1
cedazuridine
1
Watchful Waiting
1
Vital Signs
1
Tretinoin
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Lenalidomide
1
Immunotherapy, Adoptive
1
Filgrastim
1
Dexamethasone
1
Cyclophosphamide
1
Bone Marrow Transplantation
1
Azacitidine
1
Arsenic Trioxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Diseases
×
pirtobrutinib
×
Clear all
NCT05254743
2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3
Recruiting
662 enrolled